Praxis Precision Medicines Prices 2.21M Share Offering at $260, Raising Approximately $575M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 07 2026
0mins
Source: NASDAQ.COM
- Funding Scale: Praxis Precision Medicines has successfully priced an underwritten public offering of 2.21 million shares at $260 per share, raising approximately $575 million, which will provide crucial funding for the company's clinical development efforts.
- Underwriter Option: The offering includes a 30-day option for underwriters to purchase an additional 331,800 shares at the public offering price, which not only provides the company with flexibility for further financing but may also enhance market demand for its stock.
- Market Reaction: Praxis closed at $272.90 on Nasdaq, down $4.02 from the previous day, indicating a cautious market response to the offering, which could affect investor confidence in the company's future growth prospects.
- Trading Dynamics: In after-hours trading, the stock further declined to $267.55, reflecting investor concerns over short-term price volatility, which may impact subsequent financing and market performance.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
Analyst Views on PRAX
Wall Street analysts forecast PRAX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRAX is 456.71 USD with a low forecast of 95.00 USD and a high forecast of 843.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
15 Analyst Rating
14 Buy
0 Hold
1 Sell
Strong Buy
Current: 309.920
Low
95.00
Averages
456.71
High
843.00
Current: 309.920
Low
95.00
Averages
456.71
High
843.00
About PRAX
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. The Company is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Praxis Precision Medicines Appoints Dr. Orrin Devinsky as Head of Clinical Strategy
- Leadership Change: Praxis Precision Medicines has appointed renowned neurologist Dr. Orrin Devinsky as the Head of Clinical Strategy, a move that signifies a strategic deepening in the neuroscience field and is expected to accelerate the commercialization of its late-stage product portfolio.
- Industry Influence: With over four decades of experience in epilepsy and clinical neuroscience, Devinsky has led pivotal clinical trials that have driven the development of transformative therapies, bringing invaluable expertise and industry influence to Praxis.
- Scientific Contributions: Devinsky's extensive background includes over 500 peer-reviewed publications and 16 patents in epilepsy therapeutics and drug delivery, enhancing Praxis's strength in scientific research and clinical development, positioning the company to stand out in a competitive market.
- Strategic Vision: Devinsky expressed that Praxis's scientific rigor and commitment to patients set it apart in the industry, and his involvement will help guide the company's innovations in epilepsy treatment, advancing new therapies aimed at improving patient quality of life.
Continue Reading
Praxis Grants 434 Restricted Stock Units to Attract New Employees
- Employee Incentive Program: On January 2, 2026, Praxis granted 434 restricted stock units to three new non-executive employees under the 2024 Inducement Plan, aimed at attracting talent in accordance with Nasdaq Listing Rule 5635(c)(4).
- Equity Incentive Structure: These restricted stock units will vest in four equal annual installments, contingent upon the employee's continued employment with Praxis on each vesting date, thereby ensuring long-term commitment aligned with the company's growth.
- Talent Acquisition Strategy: The plan is exclusively designed to attract individuals who were not previously employed by Praxis, reflecting the company's proactive stance in talent competition and aiming to enhance its R&D capabilities in CNS disorder treatments.
- Business Development Potential: By implementing such equity incentives, Praxis not only attracts high-quality talent but also enhances its market competitiveness in the rapidly evolving biopharmaceutical industry, driving future innovation and growth for the company.
Continue Reading